Your browser doesn't support javascript.
loading
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Kowanetz, Marcin; Zou, Wei; Gettinger, Scott N; Koeppen, Hartmut; Kockx, Mark; Schmid, Peter; Kadel, Edward E; Wistuba, Ignacio; Chaft, Jamie; Rizvi, Naiyer A; Spigel, David R; Spira, Alexander; Hirsch, Fred R; Cohen, Victor; Smith, Dustin; Boyd, Zach; Miley, Natasha; Flynn, Susan; Leveque, Vincent; Shames, David S; Ballinger, Marcus; Mocci, Simonetta; Shankar, Geetha; Funke, Roel; Hampton, Garret; Sandler, Alan; Amler, Lukas; Mellman, Ira; Chen, Daniel S; Hegde, Priti S.
Afiliação
  • Kowanetz M; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080; kowanetz.marcin@gene.com mellman.ira@gene.com.
  • Zou W; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Gettinger SN; Medical Oncology, Yale Cancer Center, New Haven, CT 06510.
  • Koeppen H; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Kockx M; HistoGeneX, 2610 Antwerp, Belgium.
  • Schmid P; Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
  • Kadel EE; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Wistuba I; Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX 77054.
  • Chaft J; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Rizvi NA; Hematology and Oncology, Columbia University, New York, NY 10027.
  • Spigel DR; Sarah Cannon Research Institute, Nashville, TN 37203.
  • Spira A; Oncology Program, Virginia Cancer Specialists, Fairfax, VA 22031.
  • Hirsch FR; Medical Oncology, University of Colorado Cancer Center, Denver, CO 80045.
  • Cohen V; Oncology, Jewish General Hospital, Montreal, QC, Canada H3T 1E2.
  • Smith D; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Boyd Z; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Miley N; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Flynn S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Leveque V; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Shames DS; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Ballinger M; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Mocci S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Shankar G; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Funke R; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Hampton G; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Sandler A; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Amler L; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Mellman I; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080; kowanetz.marcin@gene.com mellman.ira@gene.com.
  • Chen DS; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
  • Hegde PS; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080.
Proc Natl Acad Sci U S A ; 115(43): E10119-E10126, 2018 10 23.
Article em En | MEDLINE | ID: mdl-30297397

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article